NCT05272150

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants With Skin of Color Who Have Moderate-to-Severe Plaque Psoriasis and/or Moderate-to-Severe Scalp Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 213 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.

Conditions

• Plaque Psoriasis
• Scalp Psoriasis

Interventions

Type	Name	Description
DRUG	Guselkumab	Participants will receive guselkumab as subcutaneous injection.
DRUG	Placebo	Participants will receive placebo as subcutaneous injection.

Timeline

• Start date: 2022-07-13
• Primary completion: 2025-05-30
• Completion: 2025-05-30
• First posted: 2022-03-09
• Last updated: 2025-09-12

Locations

94 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study